Arunava Chakravartty

Arunava is Associate Vice President of Biostatistics at Eli Lilly and Company, bringing nearly two decades of experience applying statistical innovation across oncology drug development. Previously, he spent over 12 years at Novartis, where he led global biostatistics teams supporting breast, gastrointestinal, and radio-sensitive cancer programs, advancing biomarker strategies, innovative trial designs, and quantitative decision-making from early development through registration. His expertise spans oncology, clinical pharmacology, precision medicine, and the integration of advanced statistical methodologies to improve development efficiency and patient outcomes.